company background image
NSCI

Nanalysis Scientific TSXV:NSCI Stock Report

Last Price

CA$0.90

Market Cap

CA$84.8m

7D

4.7%

1Y

-23.7%

Updated

01 Jul, 2022

Data

Company Financials +
NSCI fundamental analysis
Snowflake Score
Valuation3/6
Future Growth2/6
Past Performance0/6
Financial Health6/6
Dividends0/6

NSCI Stock Overview

Nanalysis Scientific Corp., develops, manufactures, and sells compact nuclear magnetic resonance (NMR) spectrometers and magnetic resonance imaging equipment for the pharmaceutical, biotech, chemical, security, food, materials, and education industries.

Nanalysis Scientific Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Nanalysis Scientific
Historical stock prices
Current Share PriceCA$0.90
52 Week HighCA$1.76
52 Week LowCA$0.86
Beta1.11
1 Month Change-26.23%
3 Month Change-28.00%
1 Year Change-23.73%
3 Year Change116.87%
5 Year Changen/a
Change since IPO63.64%

Recent News & Updates

Shareholder Returns

NSCICA Medical EquipmentCA Market
7D4.7%2.0%-0.8%
1Y-23.7%-39.2%-5.0%

Return vs Industry: NSCI exceeded the Canadian Medical Equipment industry which returned -38.6% over the past year.

Return vs Market: NSCI underperformed the Canadian Market which returned -4.7% over the past year.

Price Volatility

Is NSCI's price volatile compared to industry and market?
NSCI volatility
NSCI Average Weekly Movement11.8%
Medical Equipment Industry Average Movement11.8%
Market Average Movement10.1%
10% most volatile stocks in CA Market17.4%
10% least volatile stocks in CA Market4.4%

Stable Share Price: NSCI is not significantly more volatile than the rest of Canadian stocks over the past 3 months, typically moving +/- 12% a week.

Volatility Over Time: NSCI's weekly volatility (12%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
n/a107Sean Krakiwskyhttps://www.nanalysis.com

Nanalysis Scientific Corp., develops, manufactures, and sells compact nuclear magnetic resonance (NMR) spectrometers and magnetic resonance imaging equipment for the pharmaceutical, biotech, chemical, security, food, materials, and education industries. It operates through three segments: Nanalysis, RS2D, and Corporate. The company also offers software module packages; manufactures and sells cutting-edge electronics components for precision analytical instruments; and provides monitoring and supporting services for its NMR technologies.

Nanalysis Scientific Fundamentals Summary

How do Nanalysis Scientific's earnings and revenue compare to its market cap?
NSCI fundamental statistics
Market CapCA$84.79m
Earnings (TTM)-CA$2.75m
Revenue (TTM)CA$18.32m

4.6x

P/S Ratio

-30.8x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
NSCI income statement (TTM)
RevenueCA$18.32m
Cost of RevenueCA$6.86m
Gross ProfitCA$11.46m
Other ExpensesCA$14.22m
Earnings-CA$2.75m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-0.029
Gross Margin62.57%
Net Profit Margin-15.04%
Debt/Equity Ratio14.1%

How did NSCI perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is NSCI undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • PEG Ratio

Key Valuation Metric

Which metric is best to use when looking at relative valuation for NSCI?

Other financial metrics that can be useful for relative valuation.

NSCI key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue4.8x
Enterprise Value/EBITDA-55.4x
PEG Ration/a

Price to Sales Ratio vs Peers

How does NSCI's PS Ratio compare to its peers?

NSCI PS Ratio vs Peers
The above table shows the PS ratio for NSCI vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPSEstimated GrowthMarket Cap
Peer Average315.9x
SQD SQI Diagnostics
10.3xn/aCA$63.0m
MIR MedMira
94xn/aCA$87.6m
PINK Perimeter Medical Imaging AI
1088.2x66.1%CA$115.9m
TLT Theralase Technologies
71.1x65.6%CA$61.6m
NSCI Nanalysis Scientific
4.6x64.9%CA$84.8m

Price-To-Sales vs Peers: NSCI is good value based on its Price-To-Sales Ratio (4.6x) compared to the peer average (315.9x).


Price to Earnings Ratio vs Industry

How does NSCI's PE Ratio compare vs other companies in the CA Medical Equipment Industry?

Price-To-Sales vs Industry: NSCI is good value based on its Price-To-Sales Ratio (4.6x) compared to the Canadian Medical Equipment industry average (7.2x)


Price to Sales Ratio vs Fair Ratio

What is NSCI's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

NSCI PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio4.6x
Fair PS Ratio21.4x

Price-To-Sales vs Fair Ratio: NSCI is good value based on its Price-To-Sales Ratio (4.6x) compared to the estimated Fair Price-To-Sales Ratio (21.4x).


Share Price vs Fair Value

What is the Fair Price of NSCI when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate NSCI's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate NSCI's fair value for valuation analysis.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate NSCI's PEG Ratio to determine if it is good value.


Discover undervalued companies

Future Growth

How is Nanalysis Scientific forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

Future Growth Score

2/6

Future Growth Score 2/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


64.9%

Forecasted annual revenue growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if NSCI's forecast earnings growth is above the savings rate (1.6%).

Earnings vs Market: Insufficient data to determine if NSCI's earnings are forecast to grow faster than the Canadian market

High Growth Earnings: Insufficient data to determine if NSCI's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: NSCI's revenue (64.9% per year) is forecast to grow faster than the Canadian market (6.5% per year).

High Growth Revenue: NSCI's revenue (64.9% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if NSCI's Return on Equity is forecast to be high in 3 years time


Discover growth companies

Past Performance

How has Nanalysis Scientific performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-49.5%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: NSCI is currently unprofitable.

Growing Profit Margin: NSCI is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: NSCI is unprofitable, and losses have increased over the past 5 years at a rate of 49.5% per year.

Accelerating Growth: Unable to compare NSCI's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: NSCI is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (14.5%).


Return on Equity

High ROE: NSCI has a negative Return on Equity (-5.26%), as it is currently unprofitable.


Discover strong past performing companies

Financial Health

How is Nanalysis Scientific's financial position?

Financial Health Score

6/6

Financial Health Score 6/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: NSCI's short term assets (CA$33.6M) exceed its short term liabilities (CA$15.0M).

Long Term Liabilities: NSCI's short term assets (CA$33.6M) exceed its long term liabilities (CA$8.8M).


Debt to Equity History and Analysis

Debt Level: NSCI has more cash than its total debt.

Reducing Debt: NSCI's debt to equity ratio has reduced from 34.8% to 14.1% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: NSCI has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: NSCI has sufficient cash runway for 1.3 years if free cash flow continues to reduce at historical rates of 29.7% each year.


Discover healthy companies

Dividend

What is Nanalysis Scientific current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate NSCI's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate NSCI's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if NSCI's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if NSCI's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as NSCI has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

2.8yrs

Average management tenure


CEO

Sean Krakiwsky (52 yo)

3yrs

Tenure

CA$387,400

Compensation

Mr. Sean Krakiwsky, M.Sc., is Director at QUAD SYSTEMS AG from March 2022. He is a Founder of Nanalysis Scientific Corp. and has been its Chief Executive Officer, President and Director since June 4, 2019...


CEO Compensation Analysis

Compensation vs Market: Sean's total compensation ($USD299.96K) is above average for companies of similar size in the Canadian market ($USD176.25K).

Compensation vs Earnings: Sean's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: NSCI's management team is considered experienced (2.8 years average tenure).


Board Members

Experienced Board: NSCI's board of directors are not considered experienced ( 2.1 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 40.7%.


Top Shareholders

Company Information

Nanalysis Scientific Corp.'s employee growth, exchange listings and data sources


Key Information

  • Name: Nanalysis Scientific Corp.
  • Ticker: NSCI
  • Exchange: TSXV
  • Founded: NaN
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Implied Market Cap: CA$84.789m
  • Shares outstanding: 94.21m
  • Website: https://www.nanalysis.com

Number of Employees


Location

  • Nanalysis Scientific Corp.
  • Bay 1, 4600 5th Street NE
  • Calgary
  • Alberta
  • T2E 7C3
  • Canada

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/07/01 00:00
End of Day Share Price2022/06/30 00:00
Earnings2022/03/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.